Privia Health Group (NASDAQ:PRVA – Get Free Report) had its price target reduced by equities researchers at Truist Financial from $32.00 to $28.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price target would suggest a potential upside of 25.45% from the stock’s current price.
Several other research analysts have also issued reports on the stock. JMP Securities assumed coverage on shares of Privia Health Group in a report on Wednesday, December 6th. They set an “outperform” rating and a $27.00 price target for the company. JPMorgan Chase & Co. dropped their target price on shares of Privia Health Group from $43.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, November 17th. Evercore ISI dropped their target price on shares of Privia Health Group from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Wednesday. Bank of America lowered shares of Privia Health Group from a “buy” rating to a “neutral” rating and dropped their target price for the company from $27.00 to $21.00 in a report on Thursday, February 22nd. Finally, Jefferies Financial Group began coverage on shares of Privia Health Group in a report on Monday, February 26th. They issued a “buy” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.75.
View Our Latest Stock Analysis on Privia Health Group
Privia Health Group Stock Performance
NASDAQ:PRVA opened at $22.32 on Thursday. The stock has a market cap of $2.65 billion, a P/E ratio of 117.48, a price-to-earnings-growth ratio of 2.72 and a beta of 0.80. The stock’s 50-day moving average is $21.57 and its 200-day moving average is $22.56. Privia Health Group has a 1-year low of $19.17 and a 1-year high of $30.15.
Privia Health Group (NASDAQ:PRVA – Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $440.80 million for the quarter, compared to analyst estimates of $425.81 million. Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. Privia Health Group’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.14 EPS. As a group, equities analysts forecast that Privia Health Group will post 0.29 EPS for the current year.
Insider Buying and Selling at Privia Health Group
In other Privia Health Group news, Director William M. Sullivan sold 9,951 shares of the firm’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total value of $229,171.53. Following the transaction, the director now directly owns 5,464,533 shares of the company’s stock, valued at $125,848,194.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Privia Health Group news, Director William M. Sullivan sold 9,951 shares of the firm’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total value of $229,171.53. Following the transaction, the director now directly owns 5,464,533 shares of the company’s stock, valued at $125,848,194.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William M. Sullivan sold 12,000 shares of the firm’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $23.97, for a total transaction of $287,640.00. Following the completion of the transaction, the director now directly owns 5,474,484 shares in the company, valued at $131,223,381.48. The disclosure for this sale can be found here. Insiders own 57.60% of the company’s stock.
Institutional Trading of Privia Health Group
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of Privia Health Group by 201.7% in the 2nd quarter. BlackRock Inc. now owns 13,938,867 shares of the company’s stock worth $363,944,000 after acquiring an additional 9,319,052 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Privia Health Group by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,278,334 shares of the company’s stock worth $259,740,000 after acquiring an additional 274,345 shares in the last quarter. Durable Capital Partners LP bought a new stake in shares of Privia Health Group in the 2nd quarter worth $237,364,000. Wellington Management Group LLP grew its stake in shares of Privia Health Group by 1.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,656,685 shares of the company’s stock worth $107,104,000 after acquiring an additional 45,639 shares in the last quarter. Finally, Riverbridge Partners LLC boosted its stake in shares of Privia Health Group by 8.2% in the 4th quarter. Riverbridge Partners LLC now owns 4,595,358 shares of the company’s stock worth $105,831,000 after buying an additional 348,328 shares during the last quarter. 92.40% of the stock is owned by hedge funds and other institutional investors.
About Privia Health Group
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
See Also
Receive News & Ratings for Privia Health Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Privia Health Group and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
